MS-N183 · Aromatherapy and sensory support · Appraised October 30, 2026

Hedonic essential-oil aroma during breast-cancer chemotherapy

Aliases: Hedonic aroma; essential-oil inhalation

Evidence at a glance

Question: Does exposure to a pleasant essential-oil aroma during chemotherapy improve quality of life, anxiety or depression in women with breast cancer?
Finding: In a 112-participant randomized trial, the primary outcomes did not differ significantly between groups over six weeks. Exploratory associations suggested possible stress-response differences, but they do not rescue the negative primary result.
Evidence label: Primary outcomes negative
Benefit: No verified improvement in quality of life, anxiety or depression.
Certainty: Low to moderate for the null primary finding; low for exploratory secondary associations because the full text was not accessible.
Risk: Adverse-event and exact formulation details were not reported in the abstract.
Cancer-control boundary: Aroma exposure was supportive care. It did not test chemotherapy effectiveness, tumor response or survival.

Study details

Intervention: Pleasant essential-oil aroma during two consecutive chemotherapy cycles; exact oil composition and exposure protocol were not verified from the abstract.
Population: Women receiving chemotherapy for breast cancer.
Design and comparator: Randomized controlled trial; aroma plus standard chemotherapy versus standard chemotherapy alone.
Sample and follow-up: 112 randomized; assessment from the first aroma session to two cycles later, approximately six weeks.
Primary outcomes: Quality of life, anxiety and depression.
Results: No significant between-group differences for any primary outcome.
Exploratory findings: Patterns linking anxiety, quality of life, treatment beliefs and salivary cortisol differed between groups. These post-primary associations are hypothesis-generating.
Limitations: Abstract-level appraisal; blinding is difficult; exact formulation, attrition, adherence, adverse events and clinical-importance thresholds were not verified.
Funding and conflicts: Portuguese Foundation for Science and Technology grant UIDB/PSI/01662/2025; conflict statement not verified from the abstract.

Practical safety context

Essential oils can trigger headache, nausea, respiratory irritation, dermatitis or aversion. Avoid ingestion and avoid applying concentrated oils to skin. Stop exposure if chemotherapy-related nausea worsens.

Questions for the care team

Which oil, concentration and delivery method were used?
Could fragrance worsen nausea, migraine, asthma or skin sensitivity?
Are we judging benefit by primary outcomes rather than exploratory biomarker patterns?

Primary sources

Last literature search: October 30, 2026 · Record appraisal: October 30, 2026

Educational evidence summary, not medical advice. Do not change cancer treatment or supportive medications without discussing the decision with the treating team.